Quantcast
Channel: WN.com - Articles related to Actelion to enter Phase II clinical development with new dual orexin receptor antagonist in patients with insomnia (Actelion Ltd)
Viewing all articles
Browse latest Browse all 480

Actelion to present at upcoming investor conferences - Actelion 2015-2020 - Transformation on the way ...

$
0
0
(Source: Actelion Ltd) ALLSCHWIL/BASEL, SWITZERLAND - 11 January 2016- Actelion Ltd (SIX: ATLN) announced today that representatives from Actelion will present at upcoming investor conferences. Jean-Paul Clozel, Chief Executive Officer of Actelion, will present at the 34 J. P. Morgan Healthcare Conference on 12 January 2016 at 08:00 AM Pacific Standard Time / 17:00 hrs. Central European Time (CET) at the Westin St. Francis Hotel in San Francisco, US. Otto Schwarz, Chief Operating Officer of Actelion, will present at the Helvea Swiss Equities Conference on 14 January 2016. Jean-Paul Clozel will then present again at the Bank am Bellevue 'Bellevue Meets Management Seminar' on 15 January 2016....

Viewing all articles
Browse latest Browse all 480

Trending Articles



<script src="https://jsc.adskeeper.com/r/s/rssing.com.1596347.js" async> </script>